Geltor Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Later Stage VC
- Investors
-
44
Geltor General Information
Description
Producer of bespoke animal-free proteins intended to advance protein innovation. The company's products feature a proprietary AI that designs novel proteins by narrowing down amino acid sequences from extended possibilities, creating customized proteins for industries focused on beauty, health, and other applications that require specialized proteins tailored to specific functional and commercial requirements, enabling businesses to make products sustainably and grow towards a plant-based future.
Contact Information
Website
www.geltor.comCorporate Office
- 5400 Hollis Street
- Emeryville, CA 94608
- United States
Corporate Office
- 5400 Hollis Street
- Emeryville, CA 94608
- United States
Geltor Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 01-Aug-2025 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 01-Nov-2023 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 05-May-2023 | Completed | Generating Revenue | |||
| 4. Secondary Transaction - Private | 21-Feb-2022 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B) | 27-Jul-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 02-Oct-2018 | $21.2M | $21.4M | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | 04-Sep-2015 | $250K | $250K | Completed | Startup |
Geltor Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| SAFE 3 | ||||||||
| SAFE 2 | ||||||||
| SAFE 1 | 3,678,868 | $0.000100 | $0.05 | $0.61 | $0.61 | $0.61 | 7.52% | |
| Series A | 11,804,156 | $0.000100 | $0.1 | $1.24 | $1.24 | $1.24 | 24.11% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Geltor Comparisons
Industry
Financing
Details
Geltor Competitors (19)
One of Geltor’s 19 competitors is Leinco Technologies, a Private Equity-Backed company based in Saint Louis, MO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Leinco Technologies | Private Equity-Backed | Saint Louis, MO | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| FinVector | Private Debt Financed | Kuopio, Finland | ||||
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Geltor Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Geltor Patents
Geltor Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4795068-A1 | Fusion polypeptides and applications thereof | Pending | 18-Oct-2023 | ||
| WO-2025085768-A1 | Fusion polypeptides and applications thereof | Inactive | 18-Oct-2023 | ||
| EP-4508075-A1 | Compositions and methods for enhancing protein expression, solubility, and purification | Pending | 14-Apr-2022 | ||
| EP-4508075-A4 | Compositions and methods for enhancing protein expression, solubility, and purification | Pending | 14-Apr-2022 | ||
| WO-2023200996-A1 | Compositions and methods for enhancing protein expression, solubility, and purification | Inactive | 14-Apr-2022 | A61Q19/00 |
Geltor Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Geltor Investors (44)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Collateral Good | Impact Investing | Minority | ||
| Texas Medical Center | Venture Capital | Minority | ||
| Bricks Fund Tokyo | Venture Capital | Minority | ||
| Agronomics | Venture Capital | Minority | ||
| Alwyn Capital | Venture Capital | Minority |
Geltor FAQs
-
When was Geltor founded?
Geltor was founded in 2015.
-
Where is Geltor headquartered?
Geltor is headquartered in Emeryville, CA.
-
What is the size of Geltor?
Geltor has 50 total employees.
-
What industry is Geltor in?
Geltor’s primary industry is Biotechnology.
-
Is Geltor a private or public company?
Geltor is a Private company.
-
What is Geltor’s current revenue?
The current revenue for Geltor is .
-
How much funding has Geltor raised over time?
Geltor has raised $113M.
-
Who are Geltor’s investors?
Collateral Good, Texas Medical Center, Bricks Fund Tokyo, Agronomics, and Alwyn Capital are 5 of 44 investors who have invested in Geltor.
-
Who are Geltor’s competitors?
Leinco Technologies, Regenxbio, FinVector, Cristal Therapeutics, and CytomX Therapeutics are some of the 19 competitors of Geltor.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
